Barclays analyst Luke Sergott raised the firm’s price target on Thermo Fisher to $630 from $570 and keeps an Overweight rating on the shares. The analyst says 2023 will likely be a "tale of 2 cities" for traditional tools verses bioprocessing names. The year likely favors conservative management teams with a history of beating estimates, the firm tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TMO:
- Thermo Fisher joins Momentum Labs as a founding sponsor of biotech hub
- Early notable gainers among liquid option names on January 10th
- Thermo Fisher price target lowered to $505 from $525 at Wells Fargo
- Thermo Fisher completes acquisition of The Binding Site Group, sees accretion
- Aslan, Thermo Fisher announce partnership for manufacturing eblasakimab